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Summary
Objective Mifepristone, a glucocorticoid receptor antagonist,
improves clinical status in patients with Cushing’s syndrome
(CS). We examined the pattern, reliability and correlates of glo-
bal clinical response (GCR) assessments during a 6-month clini-
cal trial of mifepristone in CS.
Design Post hoc analysis of secondary end-point data from a
24-week multicentre, open-label trial of mifepristone (300–
1200 mg daily) in CS. Intraclass correlation coefficient (ICC)
was used to examine rater concordance, and drivers of clinical
improvement were determined by multivariate regression analy-
sis.
Patients Forty-six adult patients with refractory CS along with
diabetes mellitus type 2 or impaired glucose tolerance, and/or a
diagnosis of hypertension.
Measurements Global clinical assessment made by three inde-
pendent reviewers using a three-point ordinal scale (+1
= improvement; 0 = no change; 1 = worsening) based on
eight broad clinical categories including glucose control, lipids,
blood pressure, body composition, clinical appearance, strength,
psychiatric/cognitive symptoms and quality of life at Weeks 6,
10, 16, and 24.
Results Positive GCR increased progressively over time with
88% of patients having improved at Week 24 (P < 0001). The
full concordance among reviewers occurred in 766% of evalua-
tions resulting in an ICC of 0652 (P < 0001). Changes in body
weight (P < 00001), diastolic blood pressure (P < 00001), two-
hour postoral glucose challenge glucose concentration (P =
00003), and Cushingoid appearance (P = 0022) were strong
correlates of GCR.
Conclusions Mifepristone treatment for CS results in progres-
sive clinical improvement. Overall agreement among clinical
reviewers was substantial and determinants of positive GCR
included change in weight, blood pressure, glucose levels and
appearance.
(Received 18 April 2013; returned for revision 19 July 2013; finally
revised 21 August 2013; accepted 12 September 2013)
Introduction
Cushing’s syndrome (CS) is a serious multisystem disorder due to
prolonged exposure to elevated levels of cortisol. Patients with CS
experience characteristic signs and symptoms, which often include
metabolic disturbances (type 2 diabetes mellitus, impaired glucose
tolerance, insulin resistance, dyslipidaemia, obesity), cardiovascu-
lar complications (hypertension, hypercoagulability), neuropsy-
chiatric abnormalities (depression, cognitive deficit, psychosis),
reduced quality of life, altered physical appearance (moon facies,
striae, acne, hirsutism), osteoporosis and reproductive abnormali-
ties (hypogonadism, amenorrhoea). Surgical cure of the underly-
ing aetiology of CS (tumoural source of adrenocorticotropic
hormone [ACTH] or adrenal tumour) generally improves these
abnormalities; however, residual hypercortisolism is present in up
to half of patients after surgery,1–3 necessitating the use of adju-
vant medical therapy in many patients. Similar to determining
success of surgery in CS, resolution of hypercortisolism has been
the main measure of response to medical therapy because it is
widely believed that normalizing cortisol levels will resolve the
signs and symptoms of the disorder.4–7
Mifepristone, a glucocorticoid receptor antagonist, blocks the
actions of cortisol at the tissue level without a concomitant
reduction in serum cortisol. In the recent SEISMIC (Study of
the Efficacy and Safety of Mifepristone in the Treatment of
Endogenous Cushing’s Syndrome) study, administration of mife-
pristone to patients with CS resulted in improvement in dys-
glycaemia and hypertension.8 This study also showed that the
global clinical response (GCR), as determined by an independent
data review board that assessed overall clinical response based
on data from eight clinical categories, including glucose homeo-
stasis, blood pressure, lipids, body composition, strength,
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psychiatric and cognitive function, physical appearance, and
quality of life, improved in 87% of patients. We now report fur-
ther analysis of the GCR in SEISMIC, including stratification
based on clinical outcomes, time dependency and correlations
with clinical improvement during mifepristone administration.
Methods
Patients and study design
The study was approved by the Institutional Review Board at
each of the 17 research sites and conducted in accordance with
the Declaration of Helsinki. Fifty patients with ACTH-dependent
and ACTH-independent CS were enrolled in a 24-week open-
label study of mifepristone, as previously described.8 Inclusion
criteria included active hypercortisolism (defined as an elevated
24-h urinary free cortisol excretion on two collections) with
clinical signs and symptoms of CS, including type 2 diabetes
mellitus (T2DM) or impaired glucose tolerance (IGT), and/or a
diagnosis of hypertension (HT), and the presence of two of six
of the following signs and symptoms: Cushingoid appearance
(moon facies, dorsal cervical fat pad, facial plethora), increased
body weight, proximal muscle weakness, low bone mineral den-
sity, psychiatric symptoms, hirsutism and/or pigmented striae
and/or acne. For the purposes of the analysis of efficacy, there
were two primary end-points that were applied to patients based
on the presence of CS and T2DM/IGT (the C-DM cohort) or
a diagnosis of CS and hypertension without T2DM/IGT (the
C-HT cohort).
Mifepristone was initiated at 300 mg once daily orally and
increased in increments of 300 mg daily at Day 14, Week 6 and
Week 10 to a maximum of 1200 mg once daily. Investigators
could stop escalation based on tolerability and/or if the patient
had achieved sufficient clinical benefit at a given dose. The dose
could be decreased to manage adverse events (AEs) as previously
described.8 End-points were measured at baseline, Week 6, Week
10, Week 16 and Week 24. These assessments included items
from eight broad clinical categories, as shown in Table 1. Inves-
tigators graded Cushingoid appearance (facial plethora, moon-
shaped facies, dorsal cervical fat pad) on a 0–3 point scale:
0 = absent, 1 = mild, 2 = moderate, 3 = severe at each visit.
The interval change was assessed on a five-point scale: much
improved, somewhat improved, no change, somewhat worse and
much worse. The other end-point measures have been previ-
ously described.8 An independent, three-member data review
board (G.B, D.L.L., D.F.) reviewed the clinical data and assessed
the overall clinical response. Each board member independently
reviewed the data on each visit and compared those findings to
the baseline visit; the visits were presented in random sequence
blinded to dose and duration of treatment. Raters scored each
postbaseline visit for overall clinical status on a three-point ordi-
nal scale: +1 = clinically significant improvement; 0 = no
change; 1 = worse from baseline. The median score of the
three raters was used to determine GCR: a median score of +1
at any visit was defined as a positive response. Dual-energy
X-ray absorptiometry (DXA) data for body composition and
bone mineral density were available for the baseline and final
visits only.
Statistics
As previously described,8 the data review board evaluated, in a
blinded fashion, the data from the clinical parameters shown in
Table 1. An a priori positive response rate ≥30% was used to test
the overall rate of response to mifepristone; if the lower bound of
the one-sided 95% confidence interval exceeded this threshold,
the end-point was considered statistically significant. Patients with
at least 30 days of treatment [n = 46, modified intention-to-treat
(mITT) population] were evaluated in analyses of efficacy as
Table 1. Clinical parameters assessed by raters for global clinical
response
Glucose
Fasting plasma glucose test
Oral glucose tolerance tests*
Haemoglobin A1c test†
Change in glucose-lowering medications
Lipids
Total cholesterol and lipoprotein fractions and triglycerides
Blood pressure
Systolic blood pressure
Diastolic blood pressure
Change in antihypertensive medications
Body composition/bone
Body weight
Body mass index
Waist circumference
Bone resorption and formation markers
Clinical scores/appearance
Investigator-graded Cushingoid appearance‡
Investigator-graded acne scores23
Investigator-graded hirsutism scores (women only)24
Investigator-graded striae§
Strength
Sit-to-stand test (lower extremity function)25,26
Hand-grip strength test27
Psychiatric health/cognitive function
Beck depression inventory28
Trail making test (cognitive function)29,30
Quality of life
SF-36 health survey (quality of life)31
*Data for glucose and insulin levels at time 0, and 30, 60, 90, 120 min
and total AUC.
†Haemoglobin A1c at baseline and Weeks 16 and 24.
‡Cushingoid appearance (facial plethora, moon-shaped facies, dorsalcer-
vical fat pad) is graded on a 0–3 scale: 0 = absent, 1 = mild, 2 = moder-
ate, 3 = severe.
§Striae graded for each of 5 body sites (abdomen, thighs, low back, axil-
lae/arms, chest/breast) on a 0–4 scale:
0 = absent.
1 = mild with up to 2 striae, lightly violaceous or red, and up to1 cm in
width.
2 = moderate with 3 or 4 striae, violaceous or red, and >1 cm in width.
3 = major/widespread with 5 or more striae, deeply violaceous, and
>1 cm in width.
4 = severe/extensive striae that become confluent with marked skin atro-
phy.
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previously described.8 Photographs of 34 consenting patients were
available for review. A termination visit was conducted for all
patients completing the study as well as for patients with an early
termination (ET) date (Week 24/ET, n = 40). Data were imputed
using last observation carried forward (LOCF) where indicated.
Post hoc analyses were conducted to assess the time course of GCR
using the Cochran–Mantel–Haenszel (CMH) chi-square test con-
trolled for nonindependence and multiple ratings within patients,
and adjusted by the number of degrees of freedom. The impact of
age and gender on response was examined by repeated measures
analysis mixed effects model and the effect of radiation using Fish-
er’s exact test. We examined the contribution of predictive factors
on GCR in univariate and multivariate models. Factors with
meaningful correlations (P ≤ 01) were used to build a multivari-
ate regression analysis model. The agreement of raters for visits
was evaluated by intraclass correlation coefficient (ICC); the P
value was assigned using Fisher transformation for the ICC. The
ICC provides an estimate of the difference between how much
agreement was actually observed compared with that expected by
chance alone. ICC values range between 1 and 1 (<0 less than
chance agreement; 001–02 slight; 021–040 fair; 041–060
moderate; 061–080 substantial; 081–100 almost perfect
agreement).9,10 Other statistical testing used paired t-tests, Wilco-
xon signed rank tests and chi-square tests where appropriate. Sta-
tistical testing was conducted using SAS statistical software (version
9.2; Cary, NC, USA) and Microsoft Excel 2010 (Redmond, WA,
USA).
Results
Patients
The study population consisted of 46 patients (mITT popula-
tion, n = 32 female and 14 male), including 34 patients who
completed the study (i.e. through to Week 24 of treatment).8
The baseline characteristics of patients are shown in Table 2.
There were 40 patients with Cushing’s disease who had failed
prior transsphenoidal surgery, including 17 who received prior
radiation therapy (344  262 months [mean  SD] prior to
enrolment). There were three patients with ectopic ACTH syn-
drome and three with adrenal carcinoma as the cause of CS.
Twenty-five of the 46 patients had T2DM and/or impaired fast-
ing glucose (C-DM) while 21 had a diagnosis of hypertension
without T2DM and/or IGT.8 Of the 25 C-DM patients, 19
Table 2. Baseline characteristics of patients in the SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous
Cushing’s Syndrome) study. (n = 46)
Sex, n (%) Race, n (%) Ethnicity, n (%)
Male 14 (304) African American 6 (130) Hispanic 4 (87)
Female 32 (696) White 40 (870) Not Hispanic 42 (913)
Age, years Height, cm Weight, kg
Mean (SD) 445 (117) Mean (SD) 167 (110) Mean (SD) 995 (299)
Median 445 Median 166 Median 924
Minimum; maximum 26; 71 Minimum; maximum 1435; 1905 Minimum; maximum 613; 1987
Body mass index, kg/m2 Waist circumference, cm ACTH (pM)*
Mean (SD) 358 (101) Mean (SD) 119 (207) Mean (SD) 149 (139)
Median 335 Median 115 Median 110
Minimum; maximum 241; 664 Minimum; maximum 885; 1784 Minimum; maximum 15; 759
24-h UFC (nmol/24 h) Serum cortisol (nM) Late-night salivary cortisol (nM)
Mean (SD) 9394 (2 1669) Mean (SD) 6511 (2759) Mean (SD) 138 (248)
Median 3272 Median 5987 Median 83
Minimum; maximum 1183; 13 156.3 Minimum; maximum 2511; 16802 Minimum; maximum 28; 1407
Clinical signs and symptoms, n (%)
Cushingoid appearance 45 (978) Striae, hirsutism, acne 27 (587)
Proximal muscle weakness 25 (543) Low bone mass† 12 (261)
Psychiatric symptoms 23 (50)
*N = 43 for ACTH; adrenal carcinoma patients (n = 3) excluded from calculation. To convert values of ACTH to pg/ml, divide by 022. To convert
urinary free cortisol (UFC) to µg/24 h, divide by 2759. To convert cortisol to µg/l, divide by 2759.
†T below 10 at any vertebral site.
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had coexisting hypertension.8 At the start of the study, 15 of 25
C-DM patients were receiving an antidiabetic medication, and
30 of the 40 patients with a diagnosis of hypertension were tak-
ing antihypertensive medication.
Global clinical response
The proportion of patients with a positive GCR increased over
time with the greatest percentage of patients having a positive
GCR at Week 24 (88%, P < 0001 for trend, CMH chi-square;
Fig. 1). The prevalence of positive GCR was 83% (n = 40) at
the study termination visit (Week 24/ET) and was 80% (n = 46)
at the last evaluated visit (LOCF). Gender was associated with
the time to first positive GCR as well as the improvement in the
response over time (Fig. 1). As a group, the women tended to
have a slower onset of positive GCR compared with men
(P = 002 for first response by gender and P = 0003 for gender
effect over time, repeated measures analysis). The prevalence of
positive GCR at the study termination visit (Week 24/ET) and
the last evaluated visit was numerically higher in women com-
pared with men but the differences were not statistically signifi-
cant (Fig. 1). At baseline, we observed no differences in the
clinical severity of disease between men and women based upon
the frequency of typical signs and symptoms of CS; the median
number of signs and symptoms was four in both men and
women (male:female: Cushingoid appearance 100%:97%,
P = 05; increased body weight 93%:100%, P = 013; proximal
muscle weakness 71%:47%, P = 012; low bone mass 29%:25%,
P = 08; psychiatric symptoms 64%:44%, P = 02; hirsutism
and/or pigmented striae and/or acne 43%:66%, P = 015, chi-
square). Men tended to have higher pretreatment urinary free
cortisol (UFC) levels but the differences were not statistically
different from women (UFC in men [mean  SD, median]:
1815  3,664, 436 nmol/24 h vs UFC in women 552  830,
265 nmol/24 h; P = 022, Wilcoxon). Removal from the analysis
of two men with very high baseline UFC levels due to ectopic
ACTH syndrome resulted in UFC levels (mean  SD, median:
472  345, 339 nmol/24 h) similar to those in women
(P = 066, Wilcoxon). At the study termination visit (Week
24/ET) and the last evaluated visit, the prevalence of GCR was
similar among CD patients with and without prior pituitary
radiation (Week 24/ET: 867% vs 773%, P = 068, Fisher’s
exact; last evaluated visit: 882% vs 739%, P = 043, Fisher’s
exact, respectively). GCR was not significantly associated with
cohort (C-DM vs C-HT; P = 026, repeated measures analysis)
or age (P = 096, repeated measures analysis), and there
was insufficient statistical power to assess the effects of race or
ethnicity (Table 2).
Rater concordance
Overall, there was 100% agreement among the three raters in
121 of 158 (766%) evaluated patient visits, and there was a sim-
ilar degree of full agreement among raters at each assessed visit
(Week 6, 795%; Week 10, 711%; Week 16, 722%; Week 24/
ET, 825%). The ICC for rater agreement overall was 0652
(P < 0001, Fisher transformation), indicating a substantial
degree of overall agreement. Discordance occurred in 37
reviewed visits of which there was only a single case of complete
discordance (individual scores of +1, 0, 1; median 0). In the
remaining 36, two of three raters agreed and the median scores
were +1 in 19 cases, 0 in 16 cases and 1 in one case.
(a) (b)
Fig. 1 Global clinical response rate over time and by gender. (a) The prevalence of patients scored as responders increased over time (P < 0001).
Week 24/ET represents all patients who completed the study or had an early termination visit. Final visit indicates the last visit evaluated (last
observation carried forward). The a priori threshold responder rate for significance was set at ≥30%. Error bars represent the lower end of the one-
sided 95% confidence interval. (b) The global clinical response (GCR) by gender through Week 24 differed by gender (P = 002 for first GCR, and
P = 0003 for effect over time). Week 24/ET represents all patients who completed or had an early termination visit. Final visit indicates the last visit
evaluated (last observation carried forward).
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Correlates of GCR ratings
Table 3 shows the factors that predicted GCR scores in univari-
ate analyses. Entering these variables into a multiple logistic
regression model led to only four significant predictors of GCR
response: change in baseline body weight (P < 00001), change
in diastolic blood pressure (P < 00001), change in 120-min glu-
cose on an oral glucose tolerance test (oGTT) (P = 00003) and
change in Cushingoid appearance (P = 0022). Reduction in
antidiabetic medication was only modestly associated with GCR
scores in univariate analyses (P = 00631) and was not a signifi-
cant predictor in the final model. Reduction in antihypertensive
medication was not associated with GCR in the univariate
analyses (P = 0124 C-HT cohort and 04197 C-DM cohort).
When gender was entered into the model as an interacting term,
the results of the logistic regression were the same.
Cushingoid appearance was evaluated by investigator-graded
assessments as well as by photographs available for the 34 of the
46 patients who consented to standardized photography. At
baseline, 174% of patients had severe Cushingoid features, 50%
had substantial Cushingoid features, 304% had mild Cushingoid
features and 22% had absent Cushingoid features. As shown in
Fig. 2, there was a progressive improvement in Cushingoid
appearance, as assessed by the clinical site investigators
(P < 00001, Wilcoxon). Improvements in body weight, blood
pressure and glucose have been previously reported.8 Although
quality of life was not a significant correlate of positive GCR in
the multiple logistic regression model, there was a univariate
association with the Physical Composite Score (Table 3). Evalua-
tion of the SF-36 subdomains demonstrated improvement in
seven of eight measures (Fig. 3).
Discussion
The hypercortisolism of CS results in a multisystem disorder
with serious clinical sequelae. Medical therapy is usually rele-
gated to an adjuvant role following incomplete surgical extirpa-
tion or recurrence of the tumoural source of hormonal excess;
the drugs employed have typically consisted of agents that lower
cortisol secretion and have variable efficacy and tolerability.4,11,12
Mifepristone has a distinct mechanism of action: by antagoniz-
ing the effect of cortisol at the receptor level, its clinical effec-
tiveness is not dependent on cortisol reduction. Mifepristone has
been recently reported to be highly effective in improving hyper-
glycaemia associated with CS and many of the clinical manifesta-
tions of the disorder8 and thus was recently approved for use in the
United States.
In the recently reported SEISMIC study, 87% of patients with
CS achieved the key secondary study end-point of improvement
Table 3. Predictors of positive global clinical response (GCR)
Factor* Cohort†
Univariate
P
Multivariate
P
Body weight change
from baseline
Combined <00001 <00001
Diastolic blood pressure
(BP) change from baseline
C-HT 00001
Diastolic BP change from
baseline
Combined 00001 <00001
Systolic BP change from
baseline
Combined 00002
Cushingoid appearance
change from baseline
Combined 00004 0022
120-min glucose change
from baseline
Combined 00004 00003
Systolic BP change from
baseline
C-HT 00011
Systolic BP at visit C-HT 00049
Systolic BP at visit Combined 00242
Fasting glucose change
from baseline
Combined 00254
Diastolic BP at visit C-HT 00271
Waist change from baseline Combined 00318
SF-36 Physical Composite
Score change from
baseline
Combined 00339
Diastolic BP at visit Combined 00466
Diabetes medication
reduction at visit
C-DM 00631
Diabetes medication
reduction at visit
C-DM w/HTN 00855
Diastolic BP change
from baseline
C-DM w/HTN 00954
*Only factors with P ≤ 01 in univariate analysis are shown.
†C-DM = patients with diabetes mellitus/impaired glucose tolerance;
C-HT = patients with hypertension alone; Combined = C-DM and C-HT;
C-DM w/HTN = C-DM patients with a diagnosis of hypertension.
Fig. 2 Clinical improvement over time. Progressive improvement in
Cushingoid appearance in the patient population as assessed by the
clinical site investigators. P-values are compared to baseline.
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Clinical Endocrinology (2014), 80, 562–569
566 L. Katznelson et al.
in GCR during treatment with mifepristone.8 The benefits of
medical treatment in CS should be viewed in the context of a
chronic disease that may be stable or may progress. Although
the statistical assessment of efficacy used in the primary analyses
of the study assessed GCR improvement at any visit, 37% of
patients had positive GCR by Week 10 that persisted through
study end, whereas only 65% of patients had a positive GCR
during the study that was not maintained8. The additional
analyses of the clinical response data reported here demonstrate
a progressive clinical benefit of mifepristone, with the greatest
proportion of responses by the end of the study at 24 weeks.
While twice as many women were evaluated than men, the data
suggest that there may be a gender-dependent effect with mife-
pristone as there was a more rapid clinical benefit in men,
although there was no gender difference by the end of the study.
Males have been reported to have a more severe expression of
CS,13 potentially leading to a different response to glucocorticoid
blockade; however, we did not detect such differences in the
baseline severity of CS in our study population. Nonetheless,
gender-specific differences in the effectiveness of drugs are well
described although poorly understood,14 and our findings sug-
gest that a greater length of therapy may be required to docu-
ment the maximal clinical benefit for women. Although
mifepristone produces rapid and robust improvements in dys-
glycaemia in CS patients,8,15 we did not find that the presence
of T2DM/IGT influenced overall GCR. Because of the flexible
dose escalation scheme used in the study and the time lag inher-
ent in the reversal of the biological effects of hypercortisolism,
we are unable to parse out the independent effects of dose and
time on clinical improvement. The most common dose associ-
ated with first global clinical response was 600 mg, but 30% of
patients required higher doses.8
Reduction in the use of antidiabetic and/or antihypertensive
medications is an important factor in gauging clinical improve-
ment in CS. At baseline in this study, 15 patients were taking
antidiabetic medications,8 30 were taking antihypertensive medi-
cations and nine were taking both. Fourteen patients required
spironolactone to manage hypokalaemia during mifepristone
treatment.16 Lack of statistical power and possible confounding
from use of spironolactone may explain why reductions in anti-
hypertensive medications were not a significant predictor of the
GCR in the multiple regression model. High UFC levels at base-
line (>500 nmol/24 h) increased the likelihood of requiring
treatment for hypokalaemia, and the degree of increase in
UFC during mifepristone was inversely correlated with serum
potassium16.
This study used an independent physician rater board to
review and assess clinical response with the goal to have a key
study end-point of clinical assessment that simulated the clinical
practice setting of mifepristone use in CS. We noted full agree-
ment between the clinical raters in over three-quarters of their
evaluations. The statistical assessment of concordance (ICC)
among raters demonstrated a substantial degree of agreement,
which compares well with other clinical rating systems.17,18 Soni-
no et al.19 evaluated a clinical rating tool for disease severity in
CS that was based on a three-point ordinal assessment of each
of eight clinical domains, six of which were similar to the ones
used in our system (fat/weight, skin/appearance, muscle weak-
ness, mood, hypertension, diabetes), and a commonly used glo-
bal assessment tool that employed a nine-point scale for overall
illness severity and change.20 With two raters assessing 14
patients before and after the cure of CS, there was an ICC of
095 and 087, respectively, for the eight-domain tool and lower
values for the global scales (086 for severity and 067 for
Fig. 3 Quality of life measures (SF-36). Clinical
improvement over time based on evaluation of the
SF-36 subdomains demonstrated improvement in 7
of 8 measures in the patient population. P-values
are compared to baseline.
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change). Our rating system is not directly comparable to that of
Sonino19 because we used three rather than two raters, and
because Sonino’s raters directly evaluated the patients, whereas
our system used raters that did not evaluate patients in person.
Nonetheless, our system with independent raters performed sim-
ilarly to the global system used by Sonino,19 demonstrating the
practicality of our system in a clinical trial setting.
The GCR assessments in our study required raters to provide an
overall clinical appraisal of response after considering numerous
laboratory and clinical data. In multiple regression analyses, we
noted four significant predictors of a graded positive GCR
(changes in weight, 120-min oGTT glucose, diastolic blood pres-
sure and investigator-graded Cushingoid appearance). It is inter-
esting that two of these (glucose and weight) were also two
independent end-points that demonstrated the most substantial
quantitative improvement in the SEISMIC study (i.e. weight and
glucose).8 Although photographs were not available for all rated
patients, we believe that investigator-graded Cushingoid appear-
ance was a significant predictor of GCR because it was comple-
mentary to the photographs that were reviewed. It is not possible
to assess a correlation between the qualitative photographs and
the quantitative appearance ratings. Nonetheless, the change in
appearance was an important element in the raters’ judgment of
change in clinical status. Gender did not appear to modify the pre-
dictors of GCR although it was associated with the pace of
response suggesting that there were no differential treatment
effects between men and women. Although there were improve-
ments in the quality-of-life measures at the end of the study, aver-
age quality-of-life scores remained below the population norm
and did not appear to influence significantly the raters’ assessment
of overall response to treatment. Longer treatment duration may
result in further improvement. Persistent impaired quality of life
is common in CS even after long-term biochemical remission
postsuccessful surgery.21,22 Our findings suggest that the assess-
ment of multiple clinical variables can be used by clinicians to
assess mifepristone response and dosing in CS.
There are several limitations to our analysis. This Post hoc
analysis is subject to bias because it was not a predefined analy-
sis. Although these data should be interpreted with caution, they
highlight important performance characteristics of a major study
end-point. The methodology used to determine GCR was chosen
to integrate multiple clinical variables into a single rating to pro-
vide a clinically relevant assessment of response to therapy (e.g.
to simulate clinical judgement in a practice situation). This
introduces a degree of subjectivity as some end-points reviewed
were semiquantitative or qualitative (e.g. photographs) and it
also reduces statistical power. The open-label design of the study
would potentially make the reviewers more likely to assess a
positive GCR at any particular evaluated visit. We believe that
such bias was limited because the reviewers were blind to the
visit sequence (i.e. duration of treatment and dose) when patient
data were reviewed and clear patient improvement was shown
over time when analysed in chronological sequence. Our use of
a stepped approach for the logistic regression method (univari-
ate followed by multivariate) may have led us to miss an inter-
acting variable in the final model; however, other approaches
were not appropriate for the small sample size and large number
of variables in our data set.
In conclusion, treatment of Cushing’s syndrome with mifepri-
stone results in early and progressive clinical improvement in
most patients. Strong drivers of clinical response included
changes in weight, glucose, blood pressure and physical appear-
ance. Male gender may be associated with a faster response to
treatment. The independent review of variables assessing the
clinical response demonstrated robust performance as an end-
point in the clinical trial and provides evidence that appraisal of
numerous clinical parameters can be utilized when managing a
CS patient on mifepristone.
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